阿斯利康正考虑开发癌症疫苗，进军肿瘤学研究最热门的领域之一，尽管该技术的广泛适用性仍存疑问。
Plc is considering developing cancer vaccines and jumping into one of the hottest areas of oncology research where questions still remain over how broadly the technology will work.
首席执行官帕斯卡尔·索里奥周二在马德里举行的欧洲肿瘤内科学会会议结束时告诉分析师，癌症疫苗一直是公司内部大量讨论的主题。
Cancer vaccines have been a topic of very many internal discussions, Chief Executive Officer Pascal Soriot told analysts at the European Society For Medical Oncology’s conference in Madrid that wrapped up Tuesday.
他说：“我们的研发团队在过去几年里在mRNA技术方面做了大量工作。我们相信我们确实能在这一领域有所作为，未来几个月和几年你们会听到更多相关消息。”
“Our R&D team has done a lot of work in the last couple of years on mRNA technology. We believe we can actually do something in the field, and you’ll hear more about this in the months and years to come,” he said.
这是这家英国药企首次明确表示对该领域潜在工作感兴趣。在索里奥的领导下，阿斯利康已成为肿瘤学领域的强者。
It’s the first clear indication that the UK drugmaker, which has become an oncology powerhouse under Soriot’s leadership, is interested in potential work in this area.
个性化癌症疫苗针对每位患者的肿瘤量身定制，而非个性化疫苗则可用于治疗患有相似癌症的广泛患者群体。
Personalized cancer vaccines are tailored to each patient’s tumor while non-personalized vaccines would be used to treat a wide variety of patients with a similar cancer.
莫德纳与默克公司开发的一种个性化黑色素瘤癌症疫苗将患者肿瘤复发的可能性降低了42%，这一消息被肿瘤学家誉为突破。尽管如此，该结果令投资者失望。
News that a personalized melanoma cancer vaccine developed by Moderna and Merck & Co. reduced the likelihood of patients’ tumors returning by 42% has been hailed by oncologists as a breakthrough. Still, the results have disappointed investors.
阿斯利康在疫苗方面有经验，曾与牛津大学合作开发新冠疫苗，但其主要关注点一直是癌症、心脏代谢疾病以及罕见病药物。
Astra has experience with vaccines, having developed a Covid-19 shot with partner Oxford University, but its main focus has been drugs for cancer and cardiometabolic conditions, as well as rare diseases.
阿斯利康肿瘤业务部执行副总裁戴夫·弗雷德里克森周六在接受采访时表示：“我们必须在能够获胜的领域竞争，获胜意味着成为同类最佳、首创者，并利用规模优势。”
“We have to play in the spaces where we can win, and winning is about being best in class, being first, leveraging scale,” Dave Fredrickson, executive vice president of AstraZeneca’s oncology business unit, said in an interview on Saturday.
他说：“目前，在个性化癌症疫苗领域，其他公司处于更有利的位置，能够更快推进该科学进展”，但他补充称，阿斯利康的传染病部门对非个性化疫苗感兴趣。
“Today, in the personalized cancer vaccine space, there are other companies that are in a better position to be able to advance that science at pace,” he said, but added that AstraZeneca’s infectious diseases group is interested in non-personalized vaccines.
尽管目前缺乏证据表明非个性化癌症疫苗将会有效，但研究人员希望混合方法可能会产生成果。
Although there is less evidence yet that non-personalized cancer vaccines will be effective, researchers are hopeful that a hybrid approach might yield results.
会议上的数据显示，个性化疫苗对黑色素瘤有效，但阿斯利康肿瘤血液研发执行副总裁苏珊·加尔布雷思表示，她希望看到更多数据，以了解该技术是否对更广泛的癌症类型有效。
Data at the conference showed that personalized vaccines are effective for melanoma, but AstraZeneca’s Susan Galbraith, executive vice-president of oncology hematology R&D, said she wants to see more data on whether the technology will work for a wider range of cancers.
加尔布雷思对彭博新闻社表示，她对生产个性化疫苗的复杂性也持谨慎态度：“我认为成本和周转时间仍将意味着，要大规模推广给大量患者具有挑战性。”
Galbraith told Bloomberg News she is also cautious about how complex it would be to produce the personalized shots: “I think that cost and turnaround time will still mean that it’s challenging to scale out to the vast numbers of patients.”